Characterisation of cells markers associated with IKZF1plus in BCP-ALL
The presence of IKZF1 deletions has been associated with an increased relapse rate in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). There is a particular subset of IKZF1<sup>del</sup> cases called IKZF1<sup>plus</sup> (defined by the co-occurrence of IKZF1<sup>del</sup> and deletions in CDKN2A/B, PAX5, or the PAR1 region, in the absence of ERG deletions), which is also associated with worse prognosis, but some recent studies have not found major differences between the IKZF1<sup>del</sup> and IKZF1<sup>plus</sup> groups. Therefore, the IKZF1<sup>plus</sup> group still needs further comprehension and our study aims to characterise the molecular heterogeneity and identify molecular markers exclusively associated with IKZF1<sup>plus</sup>. Two independent series of cases (TARGET, n = 125 and GenLAb, n = 60) were evaluated by segregating patients into 3 groups: IKZF1<sup>plus</sup>, IKZF1<sup>del</sup>, and IKZF1<sup>wild</sup>. Differential expression analyses showed that the membrane protein-coding genes most associated with the IKZF1<sup>plus</sup> group were: KCNA5, GREB1, EPOR, SDK1, and PTPRB. Notably, KCNA5 and GREB1 differential expression levels were validated in the GenLAb validation series. Regarding copy number alterations, we observed a high frequency of VPREB1 deletions in the IKZF1<sup>plus</sup> group, as well as additional exclusive deletions in the CD200 and BTLA genes. Recent research suggests that the importance of the IKZF1<sup>plus</sup> profile varies depending on the genetic subgroup. In this scenario, we found associations between IKZF1<sup>plus</sup> and certain genes in BCP-ALL, being KCNA5 and GREB1 the most promising biomarkers for predicting IKZF1<sup>plus</sup>. A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.
Authors
- Maura Rosane Valério Ikoma-Coltutato
- Marcia Schramm (ORCID: https://orcid.org/0000-0002-3924-0517)
- Caroline P. Poubel (ORCID: https://orcid.org/0000-0003-3871-4749)
- Mecneide Mendes Lins (ORCID: https://orcid.org/0000-0002-9155-5030)
- Ana Luiza Tardem Maciel (ORCID: https://orcid.org/0000-0003-2695-4729)
- Mariana Emerenciano (ORCID: https://orcid.org/0000-0003-2337-8420)
- Thais Ferraz Aguiar
- Bruno A. Lopes (ORCID: https://orcid.org/0000-0003-1072-470X)
- Caroline Barbieri Blunck (ORCID: https://orcid.org/0000-0002-4477-6690)
- Thayana C. Barbosa (ORCID: https://orcid.org/0000-0002-9781-8647)
- Elaine Sobral da Costa (ORCID: https://orcid.org/0000-0002-5340-5816)
- Renan Garcia Gomes (ORCID: https://orcid.org/0000-0003-4950-7614)
- Marcelo Gerardin Poirot Land (ORCID: https://orcid.org/0000-0001-9792-3167)
- Marcela Braga Mansur (ORCID: https://orcid.org/0000-0002-4854-2031)
- Ariadne da Rocha Figueiredo
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Blood Cancer UK (GB)
- Hemorio (BR)
- Hospital do Câncer III (BR)
- Pro Criança Cardíaca (BR)
- Sabin Medicina Diagnostica (Brazil) (BR)
- Instituto de Medicina Integral Professor Fernando Figueira (BR)
- Instituto Nacional de Câncer - INCA (BR)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1016/j.tranon.2024.102127
- Citations
- 2
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 1.09
Funders
- Alexander von Humboldt-Stiftung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Institut National Du Cancer
- Instituto Nacional do Câncer, Ministério da Saúde
- National Cancer Institute